Table 2:
Baseline characteristics of responding patients compared to non-responders.
| Characteristics | Responders (N=11) | Non-Responders (N=26) | P Value |
|---|---|---|---|
| Age (years) | 65 [50–75] | 63 [25–75] | 0.47 |
| Male | 6 (55) | 13 (50) | >0.99 |
| Secondary AML | 2 (18) | 7 (27) | 0.69 |
| AML status | 0.27 | ||
| Primary refractory | 2 (18) | 10 (38) | |
| Relapsed | 9 (82) | 16 (62) | |
| Prior regimens | 2 [1–3] | 2 [1–6] | 0.11 |
| Int/High dose cytarabine-based | 7 (64) | 19 (73) | 0.69 |
| HMA | 5 (45) | 16 (62) | 0.47 |
| Clofarabine-based | 3 (27) | 7 (27) | >0.99 |
| Prior SCT | 1 (9) | 8 (31) | 0.22 |
| WBC (x106 /L) | 1.5 [1–5.6] | 1.8 [0.4–7.7] | 0.76 |
| Hemoglobin (g/dL) | 9.7 [7.4–13.6] | 9.5 [7.7–14.6] | 0.85 |
| Platelets (x109/L) | 34 [6–231] | 25 [2–148] | 0.03 |
| Bone marrow blasts (%) | 16 [7–68] | 37.5 [3–95] | 0.009 |
| Peripheral blasts (%) | 0 [0–41] | 23 [0–84] | 0.01 |
| Cytogenetics | |||
| Diploid | 10 (91) | 8 (31) | 0.001 |
| Complex | 0 | 12 (46) | 0.006 |
| −5/5q- and/or −7/7q- | 0 | 12 (46) | 0.006 |
AML: acute myeloid leukemia; Int: Intermediate; HMA: hypomethylating agents; SCT: stem cell transplantation; WBC: white blood cell count.